Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

@article{Walsh2020SafetyAI,
  title={Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates},
  author={Edward E Walsh and Robert W. Frenck and Ann R. Falsey and Nicholas R E Kitchin and Judith Absalon and Alejandra C Gurtman and Stephen Lockhart and Kathleen M. Neuzil and Mark J. Mulligan and Ruth Bailey and Kena A. Swanson and Ping Li and Kenneth J. Koury and Warren Vincent Kalina and David Cooper and Camila R Fontes-Garfias and Pei-Yong Shi and {\"O}zlem T{\"u}reci and Kristin R Tompkins and Kirsten E. Lyke and Vanessa N Raabe and Philip R. Dormitzer and Kathrin U. Jansen and Uğur Şahin and William C. Gruber},
  journal={The New England Journal of Medicine},
  year={2020}
}
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no vaccine is currently available. Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States. Methods In an ongoing, placebo… 
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
TLDR
Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19.
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
TLDR
All tested doses of PTX-COVID19-B were safe, well-tolerated, and provided a strong immunogenicity response, and the 40-gdose showed fewer adverse reactions than the 100-g dose, supporting further investigation of the 40,g dose.
Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
TLDR
This review assesses whether SARS-CoV-2 candidate vaccines (with approved EUA or in phase III trials) meet the criteria for an ideal Sars-Cov-2 vaccine and concludes with expectations from phaseIII trials and recommendations for phase IV studies (post-vaccine approval).
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
TLDR
The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against CO VID-19.
COVID-19 vaccines – are we there yet?
TLDR
The novel coronavirus SARS-CoV-2, the cause of the COVID-19 pandemic, is a highly infectious human respiratory pathogen to which the global population had no prior immunity and is likely to cause significant morbidity until there is a broadly effective vaccine.
SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
TLDR
The S-2P mRNA-LNP and Protein-3M-052-SE vaccines were well-tolerated and highly immunogenic in infant RMs, providing proof-of concept for a pediatric SARS-CoV-2 vaccine with the potential for durable immunity that might decrease the transmission of Sars-Cov-2 and mitigate the ongoing health and socioeconomic impacts of COVID-19.
GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults
TLDR
Overall, the safety and immunogenicity data from the phase 1 trial support further development of this vaccine.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
TLDR
The initial evaluation in mice of two updated COVID-19 mRNA vaccines designed to target emerging SARS-CoV-2 variants demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.
...
...

References

SHOWING 1-10 OF 60 REFERENCES
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
TLDR
In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
TLDR
The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
TLDR
An engineering strategy for stabilization of soluble S proteins in the prefusion conformation is described, which results in greatly increased expression, conformational homogeneity, and elicitation of potent antibody responses, and an engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
TLDR
This Ebola vaccine candidate elicited anti‐Ebola antibody responses and these results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses.
An Infectious cDNA Clone of SARS-CoV-2
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
TLDR
A fluorescence-based SARS-CoV-2 neutralization assay is reported on that detects Sars- CoV- 2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing.
...
...